Rajavelu Esther's Form 4 filing
Spero Therapeutics, Inc. (SPRO) · filed Feb 5, 2025
- Accession no.
- 0000950170-25-014859
- Filed
- Feb 5, 2025
- Trade date
- Feb 3-5, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $16.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rajavelu EstherCIK 0001903716 | Officer (CFO & CBO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2025 | Common Stock | AGrant or awardAcquired | +266,139 | $0.00 | $0 | 645,409 | Direct | |
| Feb 3, 2025 | Common Stock | AGrant or awardAcquired | +100,000 | $0.00 | $0 | 745,409 | Direct | |
| Feb 5, 2025 | Common Stock | SSaleDisposed | −20,689 | $0.78 | −$16,137.42 | 724,720 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.